IP Library Granted Patent US 9,475,781
Granted Patent B2
US 9,475,781 · App. 14/815,589 · Granted Oct 25, 2016

Fumarate analogs and uses thereof

Inventors: Matthew Duncton (San Bruno, CA); Somasekhar Bhamidipati (Foster City, CA); Jiaxin Yu (Foster City, CA); Ihab Darwish (San Carlos, CA); Rajinder Singh (Belmont, CA)
Assignee: Rigel Pharmaceuticals, Inc.
C07D257/04A61K31/41C07D401/04C07D403/12C07D405/04C07D405/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,475,781
App. No.
14/815,589
Granted
Oct 25, 2016
Kind
B2
Abstract

Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Claims (62)

1. A compound of formula (A):

wherein either:

Y 1 is X a and Y 2 is hydrogen, or Y 2 is X a and Y 1 is hydrogen;

wherein X a is selected from carboxylic acid, carboxyl ester, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl; and

R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —R 15 , wherein R 15 comprises a linking group and a compound of formula (A);

or a salt or stereoisomer thereof.

2. The compound of claim 1 , wherein the compound is of formula (Ia) or (Ib):

wherein R 15 comprises a linking group and a compound of formula (Ia) or (Ib).

3. The compound of claim 1 , wherein X a is a substituted heterocyclyl or a substituted heteroaryl, wherein the substituent on X a is X 1 , wherein X 1 is C 1-6 alkyl or a progroup.

4. The compound of claim 1 , wherein the compound is a compound of formula (IIa) or (IIb):

wherein

R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —R 15 , wherein R 15 comprises a linking group and a compound of formula (IIa) or (IIb); and

X 1 is hydrogen, C 1-6 alkyl or a progroup;

or a salt or stereoisomer thereof.

5. The compound of claim 4 , wherein R 1 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

6. The compound of claim 4 , wherein R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl.

7. The compound of claim 6 , wherein R 1 is hydrogen, methyl, ethyl, isopropyl, cyclopentyl, 4-tetrahydropyranyl, —CH 2 CH 2 OCH 3 , —CH 2 OCH 3 , —CH 2 C(O)OCH 3 , or —CH 2 CH(CH 3 ) 2 OH.

8. The compound of claim 3 , wherein X 1 is C 1-6 alkyl.

9. The compound of claim 7 , wherein X 1 is methyl or tert-butyl.

10. The compound of claim 3 , wherein X 1 is a progroup of the formula:

wherein

L 1 is a linking group;

X 2 is optional and selected from O, N and S;

R 2 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, aminoacyl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and

R 3 and R 4 are each independently optional and selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, oxo, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or

R 2 together with X 2 and either R 3 or R 4 form a heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl.

11. The compound of claim 10 , wherein X 1 is selected from:

wherein

L 1 is a C 1-6 alkyl or substituted C 1-6 alkyl;

R 5 and R 6 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or

R 5 and R 6 together with the nitrogen to which they are attached form a heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl; and

R 7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and —OR 14 where R 14 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

12. The compound of claim 11 , wherein X 1 is selected from:

wherein

R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen, alkyl and substituted alkyl.

13. The compound of claim 12 , wherein R 8 and R 9 are each independently selected from hydrogen and C 1-6 alkyl.

14. The compound of claim 13 , wherein R 8 and R 9 are each hydrogen.

15. The compound of claim 13 , wherein R 8 is hydrogen and R 9 is C 1-6 alkyl.

16. The compound of claim 12 , wherein R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen and C 1-6 alkyl.

17. The compound of claim 16 , wherein R 10 , R 11 , R 12 and R 13 are each hydrogen.

18. The compound of claim 16 , wherein one of R 10 , R 11 , R 12 and R 13 is methyl and the remaining are hydrogen.

19. The compound of claim 16 , wherein two of R 10 , R 11 , R 12 and R 13 are methyl and the remaining are hydrogen.

20. The compound of claim 1 , wherein the linking group is —(CH 2 ) n —Z y —(CH 2 ) m —,

wherein

n is an integer from 1 to 6;

m is 0 or an integer from 1 to 6;

y is 0 or 1; and

Z is O, NH, —O—P(O)(OH)—O—, S, S(O), SO 2 or —O—S(O) 2 —O—.

21. The compound of claim 20 , wherein the compound has one of the following formulae:

wherein

X 1a and X 1b are each independently selected from C 1-6 alkyl and a progroup; and

Z is O, NH, —O—P(O)(OH)—O—, S, S(O), SO 2 or —O—S(O) 2 —O—.

22. The compound of claim 1 , wherein R 1 is:

wherein X 1b is selected from C 1-6 alkyl and a progroup.

23. The compound of claim 22 , wherein the compound has one of the following formulae:

wherein X 1 and X 1b are each independently selected from C 1-6 alkyl and a progroup.

24. The compound of claim 23 , wherein X 1 and X 1b are each independently a C 1-6 alkyl.

25. The compound of claim 24 , wherein the compound has the structure:

26. The compound of claim 1 , wherein the compound is selected from:

27. The compound of claim 1 , wherein the compound is selected from:

wherein X 1 is a progroup.

28. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: DUNCTON, MATTHEW; BHAMIDIPATI, SOMASEKHAR; YU, JIAXIN; DARWISH, IHAB; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 036847/0298 →
Continuity (2)
Provisional Application 62033023 · Aug 4, 2014
Related Publication 20160039773A1 · Feb 11, 2016